August 26, 2011

Furiex Pharmaceuticals lands $15M loan

Filed under: Regional Venture News — admin @ 1:38 pm

ATLANTA, GA - Morrisville, NC-based Furiex Pharmaceuticals Inc. says it has inked a loan agreement for $15 million to support research and development on three of its clinical stage compounds. The lenders are MidCap Financial and Silcon Valley Bank.
(more…)

August 19, 2011

Cempra Pharmaceuticals gets another $5M

Filed under: Regional Venture News — admin @ 3:36 pm

ATLANTA, GA - Cempra Pharmaceuticals has raised $5 million in debt and warrants, according to U.S. Securities and Exchange Commission filings.
(more…)

August 17, 2011

VC group hunts for biotech seed investments as $125M fund takes shape

Filed under: Regional Venture News — admin @ 1:43 pm

ATLANTA, GA - Durham, NC-based venture capital fund Hatteras Venture Partners intends to announce today that it has raised $74 million for its fourth investment fund, putting it well more than halfway toward its $125 million goal.
(more…)

August 16, 2011

GeoVax gets $3.6M IPCAVD grant

Filed under: Regional Venture News — admin @ 3:00 pm

ATLANTA, GA - GeoVax Labs Inc. has landed a $3.6 million Integrated Preclinical/Clinical AIDS Vaccine Development grant.
(more…)

August 15, 2011

Embera NeuroTherapeutics Closes on $4.5 Million Continuation of Series A Financing

Filed under: Regional Venture News — admin @ 4:29 pm

SHREVEPORT, La. –Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for smoking cessation and other addictions, announced today that it has closed on $4.5 million in a continuation of its Series A financing. Embera’s existing venture investors, Louisiana Ventures, L.P., Louisiana Fund I, and Themelios Ventures, as well as private investors, participated in the round. Proceeds from this financing, combined with development grant funding from the National Institute for Drug Abuse, will support clinical development of EMB-001 through a Phase 1 safety study, enabling Embera’s clinical development programs for both smoking cessation and cocaine dependence.

(more…)

July 11, 2011

CryoLife invests $3.5M in ValveXchange

Filed under: Regional Venture News — admin @ 2:28 pm

ATLANTA, GA - CryoLife Inc. on Thursday reported a $3.5 million equity investment in ValveXchange Inc., a private medical device company spun-off out of Cleveland Clinic to develop a lifetime heart valve replacement technology platform.
(more…)

Durham biopharma Aldagen raises $1.1M

Filed under: Regional Venture News — admin @ 2:17 pm

ATLANTA, GA - Aldagen Inc., a Durham-based biopharmaceutical company developing regenerative cell therapies, has raised $1.1 million in new funding.
(more…)

July 8, 2011

Mustard Tree Instruments raises $4.8M

Filed under: Regional Venture News — admin @ 2:21 pm

ATLANTA, GA - Mustard Tree Instruments, which makes drug testing equipment, has secured $4.8 million in first-round funding, the company announced Thursday.
(more…)

July 1, 2011

Regado BioSciences raises $26M in funding

Filed under: Regional Venture News — admin @ 2:17 pm

ATLANTA, GA - Regado BioSciences has raised another $26.1 million in a Series D funding round, according to a regulatory filing made this week with the U.S. Securities and Exchange Commission.

Durham-based venture capital group Aurora Funds is among the existing investors in Regado.
(more…)

June 14, 2011

Synageva BioPharma and Trimeris Announce Merger Agreement

Filed under: Regional Venture News — admin @ 9:16 am

DURHAM, N.C.–Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders (“Synageva”), and Trimeris, Inc. (NASDAQ: TRMS) (“Trimeris”), announced today that they have entered into a definitive agreement under which Synageva will merge with Trimeris in an all-stock transaction. Upon closing, the combined company will be named Synageva BioPharma Corp., and will operate under the leadership of the Synageva management team with Sanj K. Patel serving as the President and Chief Executive Officer. In addition, the company’s board of directors will have representatives from both the existing Synageva and Trimeris boards. (more…)

« Previous PageNext Page »